share_log

8-K: CLENE REPORTS First QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

8-K: CLENE REPORTS First QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS

8-K:CLENE公布2024年第一季度财务业绩和近期经营亮点
美股SEC公告 ·  05/08 20:03

牛牛AI助手已提取核心信息

On May 8, 2024, Clene Inc., a late-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, which ended on March 31, 2024. The announcement was made through a press release and was also filed with the SEC on Form 8-K. Clene, known for its focus on neurodegenerative diseases such as ALS and MS, reported a cash balance of $27.9 million, which is expected to fund operations into Q4 2024. Research and development expenses decreased to $5.9 million from $7.4 million in the same period last year, while general and administrative expenses remained stable at $3.4 million. The company experienced a net loss of $11.1 million, or $0.09 per share, an improvement from the previous year's net loss of $11.8 million, or $0.15 per share. Clene highlighted significant progress in...Show More
On May 8, 2024, Clene Inc., a late-stage biopharmaceutical company, announced its financial results for the first quarter of 2024, which ended on March 31, 2024. The announcement was made through a press release and was also filed with the SEC on Form 8-K. Clene, known for its focus on neurodegenerative diseases such as ALS and MS, reported a cash balance of $27.9 million, which is expected to fund operations into Q4 2024. Research and development expenses decreased to $5.9 million from $7.4 million in the same period last year, while general and administrative expenses remained stable at $3.4 million. The company experienced a net loss of $11.1 million, or $0.09 per share, an improvement from the previous year's net loss of $11.8 million, or $0.15 per share. Clene highlighted significant progress in its CNM-Au8 clinical program for MS, including promising data from a Phase 2 trial and a peer-reviewed publication on the drug's protein corona. Additionally, Clene received a sub-award of $7.3 million from an NIH grant for an ALS Expanded Access Program. The company's President and CEO, Rob Etherington, expressed optimism about upcoming FDA discussions and the potential filing of a New Drug Application in the second half of the year.
2024年5月8日,后期生物制药公司Clene Inc. 公布了截至2024年3月31日的2024年第一季度的财务业绩。该公告是通过新闻稿发布的,还通过8-K表格向美国证券交易委员会提交。以专注于肌萎缩性侧索硬化症和多发性硬化症等神经退行性疾病而闻名的Clene报告的现金余额为2790万美元,预计将为2024年第四季度的运营提供资金。研发费用从去年同期的740万美元降至590万美元,而一般和管理费用稳定在340万美元。该公司的净亏损为1,110万美元,合每股亏损0.09美元,比上一年的1180万美元净亏损或每股亏损0.15美元有所改善。Clene强调了其CNM-Au8多发性硬化症临床计划的重大...展开全部
2024年5月8日,后期生物制药公司Clene Inc. 公布了截至2024年3月31日的2024年第一季度的财务业绩。该公告是通过新闻稿发布的,还通过8-K表格向美国证券交易委员会提交。以专注于肌萎缩性侧索硬化症和多发性硬化症等神经退行性疾病而闻名的Clene报告的现金余额为2790万美元,预计将为2024年第四季度的运营提供资金。研发费用从去年同期的740万美元降至590万美元,而一般和管理费用稳定在340万美元。该公司的净亏损为1,110万美元,合每股亏损0.09美元,比上一年的1180万美元净亏损或每股亏损0.15美元有所改善。Clene强调了其CNM-Au8多发性硬化症临床计划的重大进展,包括来自2期试验的令人鼓舞的数据以及关于该药物蛋白冠状的同行评审出版物。此外,克莱恩还从美国国立卫生研究院的ALS扩展准入计划拨款中获得了730万美元的次级补助金。该公司总裁兼首席执行官罗布·埃瑟灵顿对美国食品药品管理局即将举行的讨论以及下半年可能提交的新药申请表示乐观。

译文内容由第三方软件翻译。


牛牛AI助手部分由第三方人工智能模型基于资讯内容自动生成,只对中国内地以外的地区提供。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。